Discovery and therapeutic development of α-LGR5-ADC in an academic setting
Wednesday, November 4 at 16:00 GMT | 17:00 CET | 11:00 EST | 08:00 PST
Translating an academic antibody discovery program into a potential clinical therapy requires a combination of scientific validation, strategic decision-making, and effective collaboration.
In this SelectScience® webinar, Dr. Marc de la Roche, Assistant Professor & Research Group Leader at the University of Cambridge, will trace the development of an antibody–drug conjugate (ADC) targeting LGR5, from the initial generation of a therapeutic antibody through to the creation of a spin-out company preparing the program for clinical translation.
Dr. de la Roche will discuss the development and humanization of the α-LGR5 antibody, subsequent scFv generation, and the experimental evidence supporting LGR5 as a therapeutic target. He will also explore why CRC was selected as the lead indication and how the rapid internalization of LGR5, together with access to advanced drug-conjugation technology through collaborators, supported the decision to pursue an ADC-based therapeutic strategy.
By attending, you will gain insight into the key scientific and translational milestones that shaped the α-LGR5-ADC development program, how experimental data informed progression decisions, and the steps involved in taking an academic research program towards commercialization and future clinical evaluation.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes. If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on-demand recording once it becomes available.
Speakers
Who should attend?
- Academics interested in research commercialization
- Early-career researchers exploring translational science
- Individuals interested in innovation
Featured products
Request Quote for All Products
Custom Antibody Services
Vector Laboratories Inc.Absolute Antibody, a Vector Laboratories company, is the leading provider of custom antibody sequencing, engineering, production, and purification services.
What will this webinar cover?
Key learning objectives:
- Understand the academic pathway for therapeutic antibody development, from antibody discovery through to the selection of a lead α-LGR5 antibody–drug conjugate (ADC).
- Identify the key experiments required for the preclinical evaluation of antibody–drug conjugates (ADCs).
- Understand how experimental data inform decision-making and progression towards clinical development.
Join the webinar to get answers to these questions:
- How does an academic antibody discovery program progress towards clinical translation?
- How was the lead α-LGR5 antibody–drug conjugate selected?
- Which experiments are essential for preclinical ADC evaluation?
- Why was colorectal cancer chosen as the lead indication?
- How do experimental data guide ADC development and commercialization decisions?
